Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 10, 2008, Pages 1693-1696

  Ruffatti, Amelia ^a,b   Olivieri, S ^a   Tonello, M ^a   Bortolati, M ^a   Bison, E ^a   Salvan, E ^a   Facchinetti, M ^a   Pengo, V ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Cut off value

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; CRITERION RELATED VALIDITY; CRITERION VARIABLE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBOSIS; VALIDATION PROCESS;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; IMMUNOGLOBULIN G; LABORATORY TECHNIQUES AND PROCEDURES; LUPUS COAGULATION INHIBITOR; MALE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 52449102771     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03121.x     Document Type: Article

References (22)

1. Miyakis S, Lockshin MD, Atsumi M, Branch DW, Brey RL, Cervera R, Derkesen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopouos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni PL, Boffa MC. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-8.
3. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anticardiolipin antibody assay: A methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
4. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: Report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
5. Wong RC, Gillis D, Adelstein S, Baumgart K, Favaloro EJ, Hendle MJ, Homes P, Pollock W, Smith S, Steele RH, Sturgess A, Wilson RJ. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004; 36: 63-8.
6. Favaloro EJ, Wong RC, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thompson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost 2005; 31: 73-84.
7. Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifiying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995; 98: 559-65.
8. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Austr N Z Med 1990; 20: 231-6.
9. Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi G, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
10. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, Alam Z, Carey JL. IgG anticardiolipin antibody titer >40 GPL and risk of subsequent thrombo-occlusive events and death. Stroke 1997; 28: 1660-5.
11. Galli M. Antiphospholipid antibodies and thrombosis: Do test patterns identify the patients' risk? Thromb Res 2004; 114: 597-601.
12. Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005; 357: 17-33.
13. Brandt JT, Triplett DA, Alvin B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant. Thromb Haemost 1995; 74: 1185-90.
14. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-7.
15. 2-Glycoprotein-I autoantibodies. Thromb Haemost 1999; 81: 256-8.
16. 2-Glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2: 1860-2.
17. Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GR. Beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453-61.
18. Mackworth-Young CG. Antiphospholipid syndrome: Multiple mechanisms. Clin Exp Immunol 2004; 136: 393-401.
19. Di Simone N, Meroni PL, D'Asta M, Di Nicuolo F, D'Ippolito S, D'alessio MC, Caruso A. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies. A review of the literature. Ann NY Acad Sci 2007; 1108: 505-14.
20. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-54.
21. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167.
22. Erkan D, Lockshin MD. What is antiphospholipid syndrome? Curr Rheumatol Rep 2004; 6: 451-7.